IP Library Granted Patent US 11,478,473
Granted Patent B2
US 11,478,473 · App. 16/839,889 · Granted Oct 25, 2022

Sleep improving agent

Inventors: Kazunori Goto (Sapporo, JP); Jun Nakahigashi (Sapporo, JP); Atsuya Sato (Sapporo, JP); Yosuke Hirayama (Sapporo, JP); Moeri Horikoshi (Sapporo, JP); Noriyuki Kouda (Osaka, JP); Syoichiro Inoue (Osaka, JP); Ikutaro Sato (Osaka, JP); Manami Kato (Osaka, JP)
Assignees: Amino Up Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.
A61K31/4985A61P25/20A61P25/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,478,473
App. No.
16/839,889
Granted
Oct 25, 2022
Kind
B2
Abstract

The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.

Claims (17)

1. A method for improving sleep, which comprises administrating to a subject a combination of the following (a) to (c):

(a) (3S,8aS)-3-isobutylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione (Cyclo(L-Leu-L-Pro))

or a salt thereof,

(b) (3S,8aS)-3-benzylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione (Cyclo(L-Phe-L-Pro))

or a salt thereof, and

(c) (3S,8aS)-3-(4-hydroxybenzyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione (Cyclo(L-Tyr-L-Pro))

or a salt thereof,

wherein the daily dose of the Cyclo(L-Leu-L-Pro) is 10 μg-400 mg,

the daily dose of the Cyclo(L-Phe-L-Pro) is 5μg-300 mg, and

the daily dose of the Cyclo(L-Tyr-L-Pro) is 5 μg-600 mg,

wherein the subject is selected from the group consisting of

subjects who have subjective dissatisfaction with sleeping feeling selected from the group consisting of shallow asleep, insufficient sleep feeling when getting up, poor sleep, insufficient deep sleep feeling, bad dreaming, and unrecovered fatigue;

subjects who want to improve sleep quality because they are feeling fatigue;

subjects who feels disorder of autonomic nerve;

subjects who are stressed in everyday life; and

subjects with the purpose selected from the group consisting of maintaining good sleep, preventing sleep disorders, improving sleep quality, autonomic nerve-adjusting activity, and anti-stress activity.

2. The method according to claim 1 , wherein the compounds or salts thereof are administrated to the subject in the form of a pharmaceutical composition, or food and beverage composition.

Assignments (1)
CHANGE OF NAME Recorded Aug 10, 2022
From: AMINO UP CHEMICAL CO., LTD.
To: AMINO UP CO., LTD.
Reel/Frame 061144/0181 →
Priority Claims (1)
JP 2016-105477 · May 26, 2016 · national
Continuity (2)
Division 16303960
Related Publication 20200246335A1 · Aug 6, 2020